Wegovy and Ozempic: Could the new weight-loss drug also treat dementia?

weightloss
Credit: Pixabay/CC0 Public Domain

Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard to find ways to treat or prevent it. One of the avenues being explored is the new weight-loss jab, Wegovy.

Although age is by far the greatest risk factor for obesity and type 2 diabetes are also major risk factors for developing the condition. This is where Wegovy and its sister drug, Ozempic, come into the picture. Wegs and Ozempica drug to treat type 2 diabetes, both contain the same active substance called semaglutide.

Semaglutide mimics the action of a hormone, GLP-1, that is normally released from the gut after a meal. The hormone latches on to receptors in the pancreas that stimulate the release of insulin, which helps .

However, these receptors are also in “reward centers” of the brainincluding in areas controlling eating. Given that semaglutide is able to cross the blood-brain barrier (the around the brain), it is likely to directly modify to make people feel less hungry.

A Danish study that followed people with type 2 diabetes for five years found those on semaglutide or liraglutide (another ) had a lower incidence of dementia. Type 2 diabetes is more strongly associated with vascular dementia and not Alzheimer’s disease (the most common form of dementia), so only certain forms of dementia might be reduced by semaglutide.

Nevertheless, two clinical trials which began in 2021 are testing whether daily oral doses of semaglutide will slow disease progress in people in the early stages of Alzheimer’s. Since it takes a long time to develop the disease, trials are expected to be completed in 2026.

Alzheimer’s disease is thought to originate in specific regions of the cerebral cortex—the region responsible for memories and spatial navigation. But receptors for GLP-1 were not detected in the cortexmaking it unlikely that semaglutide directly activates memory networks. So how might the drug treat the disease?

The brains of Alzheimer’s disease patients accumulate sticky plaques of amyloid-beta as well as clumps of tau proteins inside brain cells. These are thought to disrupt cognition.

How Wegovy, the new weight-loss drug, works.

A clinical trial is underway here at the University of Oxford that will specifically examine tau levels in people who have high levels of amyloid-beta but have not (yet) developed dementia. It is hoped that semaglutide will reduce cortical tau levels, leading to reduced rates of cognitive decline.

Drugs recently approved in the US to treat Alzheimer’s target amyloid-beta plaques. But these drugs have proved controversial, with patients requiring hour-long infusions every two to four weeks.

These types of drug probably also target amyloid-beta around leading to potentially life-threatening side-effects such as bleeds in the brain. Alternative strategies are therefore desirable, and this is where semaglutide may shine.

Inflammation

The key link between semaglutide and reducing Alzheimer’s disease might be neuroinflammation—a state in which the is chronically inflamed.

Neuroinflammation damages the blood-brain barrierwhich is disrupted in both Alzheimer’s disease and vascular dementia. The Oxford trial examining tau is also looking at how semaglutide affects neuroinflammation (there are suggestions that semaglutide is anti-inflammatory in people with obesity).

It also reduces neuroinflammation in the brains of miceand restores glucose transport across the (something that is disrupted in people with Alzheimer’s).

Another drug, memantine—originally developed to treat diabetes—was repurposed to ease symptoms of Alzheimer’s disease, and is still prescribed for that use today. Now we eagerly await the results of the next-generation of diabetes and weight-loss drugs to see if they can prevent or treat Alzheimer’s disease.

In the meantime, there are lifestyle changes you can make to reduce your risk of developing the condition. These include keeping active, eating a maintaining a healthy weight, and quitting smoking.

This article is republished from The Conversation under a Creative Commons license. Read the original article.The Conversation

Citation: Wegovy and Ozempic: Could the new weight-loss drug also treat dementia? (2023, May 19) retrieved 27 June 2023 from https://medicalxpress.com/news/2023-05-wegovy-ozempic-weight-loss-drug-dementia.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Gordon Ramsay's son Oscar sparks comments in new photo thumbnail

Gordon Ramsay’s son Oscar sparks comments in new photo

Gordon Ramsay's youngest child, four-year-old Oscar, is clearly taking after his father – at least if his latest photo is any indication! In a new snapshot shared to the little boy's official Instagram account, which is managed by his siblings, Oscar can be seen sitting on a toy digger, while holding a spoonful of food.  The
Read More
Electrolux Group Recalls Frigidaire Rear-Controlled Ranges Due to Electrical Shock and Electrocution Hazards thumbnail

Electrolux Group Recalls Frigidaire Rear-Controlled Ranges Due to Electrical Shock and Electrocution Hazards

This recall involves select Frigidaire brand rear-controlled ranges produced from October 2023 through November 2023 with electronic control panels and the following model and serial numbers within these ranges: Model NumberSerial Number RangeFCRE3052BWVF34618193 thru VF34618322FCRE305CBWVF34601466 thru VF34601608FCRG3051BBVF34508449 thru VF34508592, VF34521553 thru VF34521696, VF34521697 thru VF34521835FCRG3051BWVF34504801 thru VF34504942FCRE3062ABVF34424109 thru VF34424252FCRG3052BWVF34510705 thru VF34510818FCRE3052BBVF34414413 thru VF34414546, VF34600745 thru VF34600888, FCRE3052BSVF34413405 thru VF34413692FCRE306CASVF34410621 thru
Read More
Developing the capacity of government to respond better to misinformation during public health emergencies thumbnail

Developing the capacity of government to respond better to misinformation during public health emergencies

The Ministry of Health and Social Services with support from WHO, trained national and regional risk communication and community engagement pillar members on Infodemic management. The spread of the COVD-19 pandemic has been followed by unprecedented and repeated waves of misinformation and disinformation generating what has been defined as an Infodemic. This overabundance of misleading
Read More
Index Of News
Total
0
Share